Shares of Aligos Therapeutics Inc (NASDAQ:ALGS) rose 3.1% on Wednesday after the company provided a progress update on its Phase 2 B-SUPREME study evaluating pevifoscorvir sodium for the treatment of chronic hepatitis B virus (HBV) infection.
The clinical-stage biopharmaceutical firm said 144 patients have now been enrolled globally, achieving enrollment targets required for both planned interim analyses. The first interim readout is expected in the first half of 2026, with a second analysis scheduled for the second half of the year.
“We look forward to our interim analyses, which will contain directional insights on how the study is tracking,” said Lawrence Blatt. “The study remains on track to complete enrollment, with topline data expected in 2027.”
The Phase 2 B-SUPREME trial is designed to assess the safety and efficacy of pevifoscorvir sodium as a monotherapy versus tenofovir disoproxil fumarate in roughly 200 treatment-naïve adults with chronic HBV over a 48-week period.
Pevifoscorvir sodium is being developed as a potential first-in-class oral small-molecule capsid assembly modulator for chronic HBV. Earlier Phase 1 trials showed the drug was generally well tolerated, with no significant safety signals, and demonstrated sustained reductions across several HBV biomarkers.
Separately, Aligos disclosed that Hardean Achneck, MD, has stepped down from his role as Executive Vice President and Chief Medical Officer, and that the company has initiated a search for a successor.